Sonoma PharmaceuticalsSNOA
13F holders, Q1 2026 (March 31)17holders +1
2new positions
1sold out
$2.13avg. 13F price*
At the end of Q1 2026, 17 institutions reported holding Sonoma Pharmaceuticals Inc. (SNOA) in their 13F filings, up 1 from Q4 2025. 2 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($42K), Vanguard Capital Management LLC ($40K) and DRW Securities, LLC ($26K).
- Company
- Sonoma Pharmaceuticals Inc.
- CUSIP
- 83558L303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3K |
| Exits | 1 | $65 |
All 13F filers, Q4 2025 → Q1 2026: 8,307 shares bought and 48,980 shares sold, net −40,673 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Geode Capital Management, LLC | 0.00% | Add +25.4% | 19,941 | $42K |
| Vanguard Capital Management LLC | 0.00% | — | 18,787 | $40K |
| DRW Securities, LLC | 0.00% | Reduce -80.3% | 12,015 | $26K |
| McKinley Carter Wealth Services, Inc. | 0.00% | No change | 11,193 | $24K |
| Morgan Stanley | 0.00% | Add +50000.0% | 2,004 | $4K |
| Citigroup Inc. | 0.00% | New | 1,425 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +219.7% | 1,231 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 500 | $1K |
| JPMorgan Chase & Co. | 0.00% | Add +1.6% | 123 | $255 |
| BlackRock, Inc. | 0.00% | No change | 113 | $241 |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 100 | $213 |
| US Bancorp \de | 0.00% | No change | 25 | $53 |
| UBS Group AG | 0.00% | No change | 6 | $13 |
| Quaker Wealth Management, LLC | 0.00% | No change | 3 | $7 |
| Danske Bank A/S | 0.00% | No change | 1 | $2 |
| Cwm, LLC | 0.00% | No change | 1 | $2 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is SNOA's weight in each manager's 13F, not the share of Sonoma Pharmaceuticals Inc. the manager owns.